Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

ClinicalTrials.gov ID: NCT01529034

Public ClinicalTrials.gov record NCT01529034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Study identification

NCT ID
NCT01529034
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Enrollment
175 participants

Conditions and interventions

Conditions

Interventions

  • USL261 Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2012
Primary completion
Mar 31, 2017
Completion
Not listed
Last update posted
Jan 19, 2023

Started 2012

United States locations

U.S. sites
31
U.S. states
21
U.S. cities
31
Facility City State ZIP Site status
United States, Arizona Phoenix Arizona
United States, Arizona Scottsdale Arizona
United States, Arizona Tucson Arizona
United States, Arkansas Little Rock Arkansas
United States, California Fresno California
United States, California Sacramento California
United States, California Ventura California
United States, Colorado Aurora Colorado
United States, Connecticut New Haven Connecticut
United States, Florida Port Charlotte Florida
United States, Florida Wellington Florida
United States, Idaho Boise Idaho
United States, Illinois Chicago Illinois
United States, Kentucky Lexington Kentucky
United States, Maryland Baltimore Maryland
United States, Michigan Detroit Michigan
United States, Minnesota Saint Paul Minnesota
United States, Missouri St Louis Missouri
United States, New Hampshire Lebanon New Hampshire
United States, New Jersey Hackensack New Jersey
United States, New York New York New York
United States, New York Stony Brook New York
United States, New York The Bronx New York
United States, North Carolina Durham North Carolina
United States, North Carolina Winston-Salem North Carolina
United States, Oklahoma Oklahoma City Oklahoma
United States, Pennsylvania Philadelphia Pennsylvania
United States, Tennessee Memphis Tennessee
United States, Tennessee Nashville Tennessee
United States, Texas Dallas Texas
United States, Texas Greenville Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01529034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01529034 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →